Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 194123, 19 pages
http://dx.doi.org/10.1155/2014/194123
Review Article

PET and PET/CT with 68Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors

1Nuclear Medicine Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, 42123 Reggio Emilia, Italy
2Regional Center of Nuclear Medicine, University of Pisa, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, 56125 Pisa, Italy
3Endocrinology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, 42123 Reggio Emilia, Italy

Received 31 August 2013; Accepted 30 October 2013; Published 13 February 2014

Academic Editors: H.-J. Biersack, H. P. Easwaran, and J. Yu

Copyright © 2014 Martina Sollini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Reubi, “Peptide receptors as molecular targets for cancer diagnosis and therapy,” Endocrine Reviews, vol. 24, no. 4, pp. 389–427, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Reubi and B. Waser, “Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 5, pp. 781–793, 2003. View at Google Scholar · View at Scopus
  3. E. Bombardieri, M. Maccauro, E. De Deckere, G. Savelli, and A. Chiti, “Nuclear medicine imaging of neuroendocrine tumours,” Annals of Oncology, vol. 12, no. 2, pp. S51–S61, 2001. View at Google Scholar · View at Scopus
  4. J. O. Olsen, R. V. Pozderac, G. Hinkle et al., “Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (OctreoScan),” Seminars in Nuclear Medicine, vol. 25, no. 3, pp. 251–261, 1995. View at Google Scholar · View at Scopus
  5. V. Briganti, R. Sestini, C. Orlando et al., “Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors,” Clinical Cancer Research, vol. 3, no. 12, pp. 2385–2391, 1997. View at Google Scholar · View at Scopus
  6. A. Chiti, V. Briganti, S. Fanti, N. Monetti, R. Masi, and E. Bombardieri, “Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours,” Quarterly Journal of Nuclear Medicine, vol. 44, no. 1, pp. 42–49, 2000. View at Google Scholar · View at Scopus
  7. A. Chiti, S. Fanti, G. Savelli et al., “Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours,” European Journal of Nuclear Medicine, vol. 25, no. 10, pp. 1396–1403, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. E. P. Krenning, D. J. Kwekkeboom, W. H. Bakker et al., “Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients,” European Journal of Nuclear Medicine, vol. 20, no. 8, pp. 716–731, 1993. View at Google Scholar · View at Scopus
  9. E. Seregni, A. Chiti, and E. Bombardieri, “Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results,” European Journal of Nuclear Medicine, vol. 25, no. 6, pp. 639–658, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Jamar, R. Fiasse, N. Leners, and S. Pauwels, “Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management,” Journal of Nuclear Medicine, vol. 36, no. 4, pp. 542–549, 1995. View at Google Scholar · View at Scopus
  11. R. Lebtahi, G. Cadiot, L. Sarda et al., “Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors,” Journal of Nuclear Medicine, vol. 38, no. 6, pp. 853–858, 1997. View at Google Scholar · View at Scopus
  12. M. Bangard, M. Béhé, S. Guhlke et al., “Detection of somatostatin receptor-positive tumours using the new 99mC-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide,” European Journal of Nuclear Medicine, vol. 27, no. 6, pp. 628–637, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Kowalski, M. Henze, J. Schuhmacher, H. R. Mäcke, M. Hofmann, and U. Haberkorn, “Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3- octreotidein comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors,” Molecular Imaging and Biology, vol. 5, no. 1, pp. 42–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Buchmann, M. Henze, S. Engelbrecht et al., “Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 10, pp. 1617–1626, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Hofmann, H. Maecke, A. R. Börner et al., “Biokinetics and imaging with the somatostatin receptor PET radioligand68Ga-DOTATOC: preliminary data,” European Journal of Nuclear Medicine, vol. 28, no. 12, pp. 1751–1757, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Wild, J. S. Schmitt, M. Ginj et al., “DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 10, pp. 1338–1347, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Ambrosini, D. Campana, L. Bodei et al., “68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 51, no. 5, pp. 669–673, 2010. View at Google Scholar · View at Scopus
  18. P. Antunes, M. Ginj, H. Zhang et al., “Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 7, pp. 982–993, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Ambrosini, D. Campana, P. Tomassetti, G. Grassetto, D. Rubello, and S. Fanti, “PET/CT with 68Gallium-DOTA-peptides in NET: an overview,” European Journal of Radiology, vol. 80, no. 2, pp. e116–e119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. P. M. Smith-Jones, C. Bischof, M. Leimer et al., “DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy,” Endocrinology, vol. 140, no. 11, pp. 5136–5148, 1999. View at Google Scholar · View at Scopus
  21. I. Virgolini, I. Szilvasi, A. Kurtaran et al., “Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients,” Journal of Nuclear Medicine, vol. 39, no. 11, pp. 1928–1936, 1998. View at Google Scholar · View at Scopus
  22. J. C. Reubi, J.-C. Schär, B. Waser et al., “Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use,” European Journal of Nuclear Medicine, vol. 27, no. 3, pp. 273–282, 2000. View at Google Scholar · View at Scopus
  23. R. C. Walker, G. T. Smith, E. Liu, B. Moore, J. Clanton, and M. Stabin, “Measured human dosimetry of 68Ga-DOTATATE,” Journal of Nuclear Medicine, vol. 54, pp. 855–860, 2013. View at Google Scholar
  24. H. Hartmann, K. Zöphel, R. Freudenberg et al., “Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations,” NuklearMedizin, vol. 48, no. 5, pp. 201–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Pettinato, A. Sarnelli, M. Di Donna et al., “68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 72–79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. E. P. Krenning, W. H. Bakker, P. P. M. Kooij et al., “Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide,” Journal of Nuclear Medicine, vol. 33, no. 5, pp. 652–658, 1992. View at Google Scholar · View at Scopus
  27. R. R. P. Warner, “Enteroendocrine tumors other than carcinoid: a review of clinically significant advances,” Gastroenterology, vol. 128, no. 6, pp. 1668–1684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. G. L. Cascini, V. Cuccurullo, and L. Mansi, “The non tumour uptake of 111In-octreotide creates new clinical indications in benign diseases, but also in oncology,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 1, pp. 24–36, 2010. View at Google Scholar · View at Scopus
  29. M. C. Smith, M. Maggi, and C. Orlando, “Somatostatin receptors in non-endocrine tumours,” Digestive and Liver Disease, vol. 36, supplement 1, pp. S78–S85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Virgolini, V. Ambrosini, J. B. Bomanji et al., “Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, pp. 2004–2010, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Fanti, V. Ambrosini, P. Tomassetti et al., “Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET,” Biomedicine and Pharmacotherapy, vol. 62, no. 10, pp. 667–671, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. B. R. Mittal, K. Agrawal, J. Shukla et al., “Ga-68 DOTATATE PET/CT in neuroendocrine tumors: initial experience,” Journal of Postgraduate Medicine Education and Research, vol. 47, pp. 1–6, 2013. View at Google Scholar
  33. M. Naji, C. Zhao, S. J. Welsh et al., “68Ga-DOTA-TATE PET vs.123I-MIBG in identifying malignant neural crest tumours,” Molecular Imaging and Biology, vol. 13, no. 4, pp. 769–775, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. Z. Win, L. Rahman, D. Towey, and A. Al-Nahhas, “68Ga-DOTATATE PET imaging in neuroectodermal tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, article S190, 2006. View at Google Scholar
  35. Z. Win, A. Al-Nahhas, D. Towey et al., “68Ga-DOTATATE PET in neuroectodermal tumours: first experience,” Nuclear Medicine Communications, vol. 28, no. 5, pp. 359–363, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Kroiss, D. Putzer, C. Uprimny et al., “Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 5, pp. 865–873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. J. B. Maurice, R. Troke, Z. Win et al., “A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, pp. 1266–1270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Sharma, A. Thakar, K. C. S. Suman et al., “68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma,” Journal of Nuclear Medicine, vol. 54, pp. 841–847, 2013. View at Google Scholar
  39. M. S. Hofman, G. Kong, O. C. Neels, P. Eu, E. Hong, and R. J. Hicks, “High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours,” Journal of Medical Imaging and Radiation Oncology, vol. 56, no. 1, pp. 40–47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Koukouraki, L. G. Strauss, V. Georgoulias, M. Eisenhut, U. Haberkorn, and A. Dimitrakopoulou-Strauss, “Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 10, pp. 1115–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Gabriel, C. Decristoforo, D. Kendler et al., “68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 508–518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Ambrosini, P. Castellucci, D. Rubello et al., “68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid,” Nuclear Medicine Communications, vol. 30, no. 4, pp. 281–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Kayani, B. G. Conry, A. M. Groves et al., “A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 50, no. 12, pp. 1927–1932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Kumar, T. Jindal, R. Dutta, and R. Kumar, “Functional imaging in differentiating bronchial masses: an initial experience with a combination of 18F-FDG PET-CT scan and 68Ga DOTA-TOC PET-CT scan,” Annals of Nuclear Medicine, vol. 23, no. 8, pp. 745–751, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Jindal, A. Kumar, B. Venkitaraman et al., “Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids,” Cancer Imaging, vol. 11, no. 1, pp. 70–75, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Jindal, A. Kumar, B. Venkitaraman, R. Dutta, and R. Kumar, “Role of 68Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids,” Korean Journal of Internal Medicine, vol. 25, no. 4, pp. 386–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Putzer, A. Kroiss, D. Waitz et al., “Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, pp. 364–372, 2013. View at Google Scholar
  48. V. Ambrosini, C. Nanni, M. Zompatori et al., “68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 4, pp. 722–727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Putzer, M. Gabriel, B. Henninger et al., “Bone metastases in patients with neuroendocrine tumor: 68Ga- DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy,” Journal of Nuclear Medicine, vol. 50, no. 8, pp. 1214–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. A. R. Haug, C. J. Auernhammer, B. Wängler et al., “68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 51, no. 9, pp. 1349–1356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Dimitrakopoulou-Strauss, V. Georgoulias, M. Eisenhut et al., “Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using 68Ga-DOTATOC PET and comparison with 18F-FDG PET,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 7, pp. 823–830, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Sollini, D. Farioli, A. Froio et al., “Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients,” Journal of Thoracic Oncology, vol. 8, pp. 1095–1101, 2013. View at Google Scholar
  53. D. Waitz, D. Putzer, H. Kostron, and I. J. Virgolini, “Treatment of high-grade glioma with radiolabeled peptides,” Methods, vol. 55, no. 3, pp. 223–229, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Heute, H. Kostron, E. Von Guggenberg et al., “Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC,” Journal of Nuclear Medicine, vol. 51, no. 3, pp. 397–400, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. J. E. Gains, J. B. Bomanji, N. L. Fersht et al., “177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma,” Journal of Nuclear Medicine, vol. 52, no. 7, pp. 1041–1047, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Afshar-Oromieh, F. L. Giesel, H. G. Linhart et al., “Detection of cranial meningiomas: comparison of Ga-DOTATOC PET/CT and contrast-enhanced MRI,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, pp. 1409–1415, 2012. View at Google Scholar
  57. S. Milker-Zabel, A. Zabel-du Bois, M. Henze et al., “Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET,” International Journal of Radiation Oncology Biology Physics, vol. 65, no. 1, pp. 222–227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Gehler, F. Paulsen, M. T. Öksüz et al., “[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning,” Radiation Oncology, vol. 4, no. 1, article 56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Nyuyki, M. Plotkin, R. Graf et al., “Potential impact of 68Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 2, pp. 310–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Graf, M. Plotkin, I. G. Steffen et al., “Magnetic resonance imaging, computed tomography, and 68Ga-DOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy—a case series,” Head and Face Medicine, vol. 8, no. 1, article 1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Henze, J. Schuhmacher, P. Hipp et al., “PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-Octreotide: first results in patients with meningiomas,” Journal of Nuclear Medicine, vol. 42, no. 7, pp. 1053–1056, 2001. View at Google Scholar · View at Scopus
  62. M. Henze, A. Dimitrakopoulou-Strauss, S. Milker-Zabel et al., “Characterization of 68Ga-DOTA-D-Phe1-Tyr 3-octreotide kinetics in patients with meningiomas,” Journal of Nuclear Medicine, vol. 46, no. 5, pp. 763–769, 2005. View at Google Scholar · View at Scopus
  63. H. Hänscheid, R. A. Sweeney, M. Flentje et al., “PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, pp. 1284–1288, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. B. G. Conry, N. D. Papathanasiou, V. Prakash et al., “Comparison of 68Ga-DOTATATE and 18F- fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 49–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Treglia, P. Castaldi, M. F. Villani et al., “Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, pp. 569–580, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Miederer, S. Seidl, A. Buck et al., “Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 1, pp. 48–52, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Koukouraki, L. G. Strauss, V. Georgoulias et al., “Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 4, pp. 460–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Middendorp, I. Selkinski, C. Happel, W. T. Kranert, and F. Grünwald, “Comparison of positron emission tomography with [18F]FDG and [68Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 1, pp. 76–83, 2010. View at Google Scholar · View at Scopus
  69. M. Gabriel, U. Andergassen, D. Putzer et al., “Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 1, pp. 92–99, 2010. View at Google Scholar · View at Scopus
  70. A. Versari, M. Sollini, A. Frasoldati et al., “Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients,” Thyroid. In press.
  71. J. Vasamiliette, P. Hohenberger, S. Schoenberg et al., “Treatment monitoring with 18F-FDG PET in metastatic thymoma after 90Y-Dotatoc and selective internal radiation treatment (SIRT),” Hellenic Journal of Nuclear Medicine, vol. 12, no. 3, pp. 271–309, 2009. View at Google Scholar · View at Scopus
  72. R. Dutta, A. Kumar, P. K. Julka et al., “Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation,” Interactive Cardiovascular and Thoracic Surgery, vol. 11, no. 6, pp. 732–736, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Froio, M. Sollini, A. Fraternali et al., “Thymic neoplasms evaluation: role of 68Ga-peptide and [18F]FDG PET/CT,” Journal of Nuclear Medicine, vol. 54, no. 5, supplement 1, article 1632, 2013. View at Google Scholar
  74. C. Schneider, M. Schlaak, M. Bludau, B. Markiefka, and M. C. Schmidt, “68Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma,” Clinical Nuclear Medicine, vol. 37, pp. 1108–1111, 2012. View at Google Scholar
  75. M. C. Schmidt, K. Uhrhan, B. Markiefka et al., “68Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell Carcinoma,” International Journal of Clinical and Experimental Medicine, vol. 5, pp. 363–366, 2012. View at Google Scholar
  76. A. Salavati, V. Prasad, C.-P. Schneider, R. Herbst, and R. P. Baum, “Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology,” Annals of Nuclear Medicine, vol. 26, pp. 365–369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Epstude, K. Tornquist, C. Riklin et al., “Comparison of, (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized merkel cell carcinoma,” Clinical Nuclear Medicine, vol. 38, pp. 283–284, 2013. View at Google Scholar
  78. F. Elgeti, H. Amthauer, T. Denecke et al., “Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours,” NuklearMedizin, vol. 47, no. 6, pp. 261–265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Casini Raggi, A. Calabrò, D. Renzi et al., “Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa,” Clinical Cancer Research, vol. 8, no. 2, pp. 419–427, 2002. View at Google Scholar · View at Scopus
  80. A. Haug, R. Cindea-Drimus, C. Auernhammer, G. Schmidt, P. Bartenstein, and M. Hacker, “68Ga-DOTATATE PET/CT in the diagnosis of recurrent neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 53, supplement 1, article 419, 2012. View at Google Scholar
  81. K. Desai, J. Watkins, N. Woodward et al., “Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin,” Journal of Clinical Gastroenterology, vol. 45, no. 1, pp. e8–e11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Brogsitter, K. Zöphel, G. Wunderlich, E. Kämmerer, A. Stein, and J. Kotzerke, “Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma,” Nuclear Medicine Communications, vol. 34, pp. 47–49, 2013. View at Google Scholar
  83. M. Souvatzoglou, T. Maurer, U. Treiber, G. Weirich, B. J. Krause, and M. Essler, “68Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases,” Nuklearmedizin, vol. 48, no. 5, pp. N52–N54, 2009. View at Google Scholar · View at Scopus
  84. W. Luboldt, K. Zöphel, G. Wunderlich, A. Abramyuk, H.-J. Luboldt, and J. Kotzerke, “Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT,” Molecular Imaging and Biology, vol. 12, no. 1, pp. 78–84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. O. Alonso, J. P. Gambini, G. Lago, J. Gaudiano, A. Quagliata, and H. Engler, “In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer,” Clinical Nuclear Medicine, vol. 36, no. 11, pp. 1063–1064, 2011. View at Google Scholar · View at Scopus
  86. C. Von Falck, T. Rodt, H. Rosenthal et al., “68Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 5, article 1034, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. E. Woff, C. Garcia, L. Tant et al., “Imaging of tumour-induced osteomalacia using a gallium-68 labelled somatostatin analogue,” BMJ Case Reports, vol. 2010, Article ID bcr0220102750, 2010. View at Google Scholar
  88. R. J. Clifton-Bligh, M. S. Hofman, E. Duncan et al., “Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, pp. 687–694, 2013. View at Google Scholar
  89. C. Mawrin, S. Schulz, S. U. Pauli et al., “Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 1, pp. 13–19, 2004. View at Google Scholar · View at Scopus
  90. U. Kumar, S. I. Grigorakis, H. L. Watt et al., “Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology,” Breast Cancer Research and Treatment, vol. 92, no. 2, pp. 175–186, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. C.-Z. Qiu, S.-Z. Zhu, Y.-Y. Wu, C. Wang, Z.-X. Huang, and J.-L. Qiu, “Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer,” World Journal of Gastroenterology, vol. 12, no. 13, pp. 2011–2015, 2006. View at Google Scholar · View at Scopus
  92. K. Pazaitou-Panayiotou, E. Tiensuu Janson, T. Koletsa et al., “Somatostatin receptor expression in non-medullary thyroid carcinomas,” Hormones (Athens), vol. 11, pp. 290–296, 2012. View at Google Scholar
  93. K. Szepeshazi, A. V. Schally, A. Nagy, B. W. Wagner, A. M. Bajo, and G. Halmos, “Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas,” Cancer, vol. 98, no. 7, pp. 1401–1410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. J. C. Reubi, B. Waser, J.-C. Schaer, and J. A. Laissue, “Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands,” European Journal of Nuclear Medicine, vol. 28, no. 7, pp. 836–846, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Palmieri, L. Montella, C. Aiello et al., “Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract,” Amino Acids, vol. 32, no. 3, pp. 395–400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. T. Florio, L. Montella, A. Corsaro et al., “In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors,” Anticancer Research, vol. 23, no. 3, pp. 2465–2471, 2003. View at Google Scholar · View at Scopus
  97. M. Bläker, M. Schmitz, A. Gocht et al., “Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas,” Journal of Hepatology, vol. 41, no. 1, pp. 112–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. V. A. S. H. Dalm, L. J. Hofland, C. M. Mooy et al., “Somatostatin receptors in malignant lymphomas: targets for radiotherapy?” Journal of Nuclear Medicine, vol. 45, no. 1, pp. 8–16, 2004. View at Google Scholar · View at Scopus
  99. S. S. Lum, W. S. Fletcher, M. S. O'Dorisio, R. W. Nance, R. F. Pommier, and M. Caprara, “Distribution and functional significance of somatostatin receptors in malignant melanoma,” World Journal of Surgery, vol. 25, no. 4, pp. 407–412, 2001. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Arena, F. Barbieri, S. Thellung et al., “Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity,” Journal of Neuro-Oncology, vol. 66, no. 1-2, pp. 155–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Papotti, L. Macri, A. Pagani, F. Aloi, and G. Bussolati, “Quantitation of somatostatin receptor type 2 in neuroendocrine (Merkel cell) carcinoma of the skin by competitive RT-PCR,” Endocrine Pathology, vol. 10, no. 1, pp. 37–46, 1999. View at Google Scholar · View at Scopus
  102. M. C. Zatelli, F. Tagliati, J. E. Taylor, R. Rossi, M. D. Culler, and E. C. Degli Uberti, “Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2161–2169, 2001. View at Publisher · View at Google Scholar · View at Scopus
  103. E. Mato, X. Matías-Guiu, A. Chico et al., “Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 7, pp. 2417–2420, 1998. View at Publisher · View at Google Scholar · View at Scopus
  104. D. Ferone, M. Arvigo, C. Semino et al., “Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation,” American Journal of Physiology—Endocrinology and Metabolism, vol. 289, no. 6, pp. E1044–E1050, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. N. Dizeyi, L. Konrad, A. Bjartell et al., “Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines,” Urologic Oncology, vol. 7, no. 3, pp. 91–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. F. Kosari, J. M. A. Munz, C. D. Savci-Heijink et al., “Identification of prognostic biomarkers for prostate cancer,” Clinical Cancer Research, vol. 14, no. 6, pp. 1734–1743, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Saveanu and P. Jaquet, “Somatostatin-dopamine ligands in the treatment of pituitary adenomas,” Reviews in Endocrine and Metabolic Disorders, vol. 10, no. 2, pp. 83–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. T. Tateno, M. Kato, Y. Tani, K. Oyama, S. Yamada, and Y. Hirata, “Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas,” Endocrine Journal, vol. 56, no. 4, pp. 579–584, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. A. Fusco, G. Gunz, P. Jaquet et al., “Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas,” European Journal of Endocrinology, vol. 158, no. 5, pp. 595–603, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Yoshihara, O. Isozaki, N. Hizuka et al., “Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting longterm response to octreotide therapy,” Endocrine Journal, vol. 54, no. 1, pp. 133–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Saveanu, I. Morange-Ramos, G. Gunz, H. Dufour, A. Enjalbert, and P. Jaquet, “A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies,” European Journal of Endocrinology, vol. 145, no. 1, pp. 35–41, 2001. View at Google Scholar · View at Scopus
  112. T. Florio, F. Barbieri, R. Spaziante et al., “Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A Multi-Center Study,” Endocrine-Related Cancer, vol. 15, no. 2, pp. 583–596, 2008. View at Publisher · View at Google Scholar · View at Scopus